Multicolor illustration of pills with psychedelic designs inside them
Johns Hopkins joins multi-university project to develop fellowships and training programs in psychedelic therapy. Multicolor illustration of pills with psychedelic designs inside them - Psilocybin-the substance that puts the magic in magic mushrooms-can help people emerge from depression , spur others to quit smoking , and even allow those facing terminal cancer to make peace with death. The Food and Drug Administration and the Drug Enforcement Administration classified psilocybin as a "breakthrough therapy" for depression in 2018, a move many see as paving the way for the eventual approval of the drug as a treatment for mental health conditions. Patients are already clamoring for the treatment, which for many brings dramatic results in just a few sessions. The impending challenge? Training psychiatrists and other clinicians to administer psychedelics, which are significantly different from other classes of drugs prescribed for mental health. A new $900,000 grant from the psychedelics-focused Heffter Research Institute will allow researchers from Johns Hopkins, Yale University, and New York University to build out a postdoctoral fellowship and gold-standard training program in psychedelic therapy. While some organizations have certification programs in psychedelics, they are often based on anecdotal observations, not hard data.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
